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AP-1 has been shown to behave as a redox-sensitive
transcription factor that can be activated by both oxi-
dant and antioxidant stimuli. However, the mechanisms
involved in the activation of AP-1 by antioxidants are
largely unknown. In this study we show that the struc-
turally unrelated antioxidant agents pyrrolidine dithio-
carbamate (PDTC), butylated hydroxyanisole, and N-
acetylcysteine activated JNK (c-Jun NH2-terminal ki-
nase) in Jurkat T cells. This activation differed substan-
tially from that mediated by phorbol 12-myristate 13-
acetate (PMA) and Ca21 ionophore or produced by
costimulation with antibodies against the T cell recep-
tor-CD3 complex and to CD28. The activation of JNK by
classical T cell stimuli was transient, whereas that me-
diated by PDTC and butylated hydroxyanisole (but not
N-acetylcysteine) was sustained. The kinetics of JNK
activation correlated with the expression of c-junwhich
was transient after stimulation with PMA plus iono-
phore and prolonged in response to PDTC, which also
transiently induced c-fos. In addition, JNK activation by
PMA plus ionophore was sensitive to inhibitors of sig-
naling pathways involving Ca21, protein kinase C, and
tyrosine phosphorylation, which failed to inhibit the
activation mediated by PDTC. Transfection of trans-
dominant negative expression vectors of ras and raf,
together with AP-1-dependent reporter constructs, as
well as Western blot analysis using anti-ERK (extracel-
lular signal-regulated kinase) antibodies, indicated that
the Ras/Raf/ERK pathway did not appear to mediate the
effect of the antioxidant. However, the combined treat-
ment with PDTC and PMA, two agents that synergize on
AP-1 activation, resulted in the persistent phosphoryla-
tion of ERK-2. In conclusion, our results identify JNK as
a target of antioxidant agents which can be regulated
differentially under oxidant and antioxidant conditions.
The transcription factor AP-1 plays a central role by inte-
grating the signals elicited by a large number of extracellular
stimuli including growth factors, phorbol esters, UV light, and
cytokines (1). Homodimers of members of the Jun family of
transcription factors and heterodimers formed with these
members and those of the Fos family comprise the AP-1 tran-
scription factor, which binds to the TRE1 site to regulate gene
transcription (1, 2).
The capacity of AP-1 to respond to a wide array of extracel-
lular signals is largely mediated by the transcription factors
that regulate the c-fos and c-jun promoters whose binding and
activity are in turn regulated through different signaling path-
ways (2–4). Thus, the major regulatory element within the
c-fos promoter, the serum response element (SRE), is recog-
nized by a complex that contains the ternary complex factor
(TCF)/Elk-1 and the serum response factor (3). TCF/Elk-1 is
phosphorylated rapidly in response to a variety of stimuli by
the mitogen-activated protein kinases ERK-1 and ERK-2,
which are activated by the Ras/Raf/ERK kinase cascade (4, 5).
The sequential activation and phosphorylation of ERK and
TCF/Elk-1 facilitate the SRE ternary complex formation and
the subsequent transcriptional induction of c-fos (6–8). Tran-
scription of c-jun is activated by binding of preformed ho-
modimers of c-Jun or heterodimers of c-Jun and ATF-2 to the
TRE of the c-jun promoter. Both transcription factors c-jun and
ATF-2 are phosphorylated by another group of mitogen-acti-
vated protein kinases denominated JNKs/SAPKs (c-Jun NH2-
terminal kinases/stress-activated protein kinases) (9–11),
which are activated early by upstream signal transduction
pathways involving kinase cascades different from those regu-
lating the ERKs (12, 13).
Although several growth factors stimulate the ERK pathway
and induce c-fos involving the phosphorylation of TCF/Elk-1,
exposure of cells to stress induced by UV radiation (14) or by
protein synthesis inhibitors (15), which occurred with c-fos
gene expression, did not involve activation of the ERK path-
way. Recently, studies on the mechanisms involved in TCF/
Elk-1 phosphorylation indicated that this factor is a point of
convergence of mitogen-activated protein kinases/ERKs and
JNK/SAPK signaling pathways, since JNKs/SAPKs can also
phosphorylate TCF/Elk-1 in response to a variety of stimuli
(13, 16–19). Therefore, JNK activation itself could account for
AP-1 activation, since TCF/Elk-1, c-Jun, and ATF-2, factors
critically involved in the transcription of c-fos and c-jun, are
targets that can be phosphorylated by this kinase.
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The activity of the AP-1 and NFkB transcription factors is
regulated differentially in T lymphocytes in response to
changes in the cell redox state (20). The use of antioxidants
with radical scavenger properties has evidenced a role for re-
active oxygen intermediates, generated under prooxidant con-
ditions, on the activation of NFkB. Thus, the activation of
NFkB in response to oxidative stress is inhibited by several
structurally unrelated antioxidants including dithiocarba-
mates (21–24), the antioxidant enzyme thioredoxin (23–25),
and the glutathione precursor N-acetylcysteine (21, 26, 27).
AP-1 is also activated by a number of stimuli that generate
oxidative stress (23, 28–31). However, these antioxidants that
block NFkB activation efficiently paradoxically stimulate the
DNA binding and transcriptional activities of AP-1 involving
induction of the c-fos and c-jun mRNAs (23, 24, 32) and the
transcriptional activation of the SRE (23). Therefore, signals
triggered under both prooxidant and antioxidant conditions
can lead to the activation of AP-1.
To understand the mechanisms by which antioxidants acti-
vate AP-1, we analyzed their effects on different signal trans-
duction pathways involved in T cell activation. We found that
different antioxidant agents stimulate JNK activity. Further-
more, we studied the antioxidant-induced signaling in T lym-
phocytes using pyrrolidine dithiocarbamate (PDTC), a potent
antioxidant agent that activates AP-1. Our results are dis-
cussed in the context of recent works that implicate JNK as a
mediator in the activation of both c-fos and c-jun transcrip-
tional expression.
EXPERIMENTAL PROCEDURES
Cell Culture, Reagents, and Monoclonal Antibodies—The human
Jurkat T cell line was grown in RPMI 1640 with GLUTAMAX-I (Life
Technologies, Inc.) supplemented with 10% fetal calf serum. Phorbol
12-myristate 13-acetate (PMA), PDTC, butylated hydroxyanisole
(BHA), N-acetylcysteine, and the calcium ionophore A23187 were pur-
chased from Sigma. Cyclosporin A was from Sandoz. Bisindolylmaleim-
ide and herbimycin A were from Calbiochem. The purified activating
anti-CD28.2 monoclonal antibody was provided by Dr. D. Olive, and the
anti-CD3 SPV-T3 has been described previously (33).
RNA Analysis—Jurkat cells were incubated with PDTC, PMA plus
ionophore, or pretreated with PDTC and then exposed to PMA plus
ionophore. After various time points, cells were harvested, and total
RNA was isolated using the Ultraspec system (Biotox Laboratories,
Inc.). For dot-blot analysis, RNA from each sample (10 mg) was dena-
tured and blotted onto nitrocellulose membranes in a Bio-Dot SF mi-
crofiltration apparatus (Bio-Rad). For Northern blot analysis denatured
RNA (20 mg) was electrophoresed on a 1% agarose gel and blotted onto
a nitrocellulose membrane.
After UV cross-linking, the filters were hybridized with the corre-
sponding specific probes: a 0.8-kb BglII-NcoI fragment of c-fos cDNA, a
0.8-kbHindIII-PstI fragment of c-jun cDNA, a 1.8-kb EcoRI fragment of
human PAC-1 cDNA (34), and a 0.6-kb HindIII-BamHI fragment of
b-actin cDNA.
Plasmid Constructs—The plasmids used for the expression of acti-
vated v-Ha-ras, dominant negative ras, and dominant negative rafwere
provided by Dr. D. Cantrell. These plasmids were generated by insert-
ing a 0.7-kb BamHI fragment of v-Ha-ras (activated ras), a 4.4-kb
XhoI-BamHI fragment of c-Ha-ras N17 (ras dominant negative), and a
0.8-kb polymerase chain reaction fragment containing a carboxyl-ter-
minal truncated form of raf (dominant negative) into the pEFBOS
expression vector (35). The IL-2Luc reporter construct containing the
2326 to 145 human IL-2 promoter/enhancer region fused to the lucif-
erase gene (36) was provided by Dr. G. Crabtree. The 73colLuc and
60colLuc plasmids including the AP-1-responsive (273/163 base pairs)
and the AP-1-unresponsive (260/163 base pairs) regions of the human
collagenase promoter fused to the luciferase gene have been described
previously (37) and were provided by Dr. M. Karin.
Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA)—
Small scale nuclear extracts were obtained from 107 Jurkat cells fol-
lowing a procedure described previously (38) but included in the ex-
tracting buffers 10 mM sodium orthomolybdate, 1 mg/ml aprotinin, 1
mg/ml leupeptin, 1 mg/ml pepstatin, and 0.5 mM phenylmethylsulfonyl
fluoride. EMSAs were performed as described (32) except for the bind-
ing reactions that were performed using 5 mg of nuclear proteins and 1
mg of poly(dIzdC) DNA carrier. The double-stranded oligonucleotide
used as a probe in EMSAs, 59-GCCCCCTCTGACTCATGCTGACA-39,
included the 268 to 246 base pairs of the CD11c promoter (32) con-
taining an AP-1 consensus site.
Transfection Experiments—Jurkat cells (107) were transfected with
Lipofectin (Life Technologies, Inc.) as recommended by the manufac-
turer. Briefly, exponentially growing cells (3–7 3 105/ml) were washed
twice with phosphate-buffered saline, resuspended in Opti-MEM (Life
Technologies, Inc.), and incubated for 12 h at 37 °C with a mixture of 5
mg/ml plasmid DNA and 10 mg/ml Lipofectin in 1 ml of Opti-MEM.
Then, cells were diluted with 14 ml of complete medium (RPMI and 10%
fetal bovine serum) and incubated for 36 h. Cells were then treated with
different stimuli for 12 additional h, collected by centrifugation, and
luciferase activity was determined following instructions described in a
luciferase assay kit (Promega, Madison, WI). In cotransfection experi-
ments with expression vectors, the same protocol was followed, but the
reporter and expression plasmids were added at concentrations of 5 and
10 mg/ml, respectively, and the Lipofectin to 10 mg/ml.
Western Blot Analysis—Western blot was performed as described
previously (39) with the following modifications. Cells (106) were
washed and lysed in 200 ml of buffer A (20 mM Hepes, pH 7.8, 50 mM
b-glycerophosphate, 0.1 mM sodium orthovanadate, 0.5% Triton X-100,
2 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 2 mg/ml aprotinin, 2
mg/ml leupeptin, 3 nM okadaic acid). After vortex, cells were kept on ice
for 15 min and microcentrifuged for 15 min. Supernatants were col-
lected, mixed with loading buffer, and separated by 8% SDS-polyacryl-
amide gel electrophoresis. Gels were transferred to Immobilon-P mem-
branes and then incubated with blocking solution (5% w/v skim milk
TBS-T (TBS, 0.05% Tween 20)) for 60 min at 45 °C, washed three times
in TBS-T, and incubated with anti-ERK 1, 2 (Zymed, San Francisco)
0.1% v/v in TBS-T, 5% w/v skim milk. Then, membranes were washed
six times for 5 min each in 0.5% w/v skim milk in TBS-T, and peroxi-
dase-labeled goat anti-mouse IgG (ICN) (0.1% v/v in TBS-T) was incu-
bated for 60 min at room temperature. After three washes with TBS-T
and one with TBS, membrane-bound antibody was visualized by ECL
detection reagent (Amersham Corp.).
In-gel Kinase Assays—In-gel kinase assays were performed as de-
scribed previously (40) with some modifications. Lysates from 106 cells
were diluted in Laemmli sample buffer and separated by electrophore-
sis in a 10% SDS-polyacrylamide gel polymerized in the presence of
GST-c-Jun1–79 fusion protein. GST-c-Jun protein was isolated from 250
ml of bacterial cells expressing pGEX-c-Jun1–79 plasmid (provided by
Dr. R. Davis) using GSH-Shepharose 4B beads (Pharmacia Biotech
Inc.). After electrophoresis, the gel was washed twice for 15 min in 100
ml of 20% v/v 2-propanol, 50 mM Hepes, pH 7.6, and then equilibrated
with two 15-min changes of 100 ml of buffer A (50 mM Hepes, pH 7.6, 5
mM b-mercaptoethanol). Proteins were denatured by incubating the gel
twice for 15 min in 100 ml of 6 M urea in buffer A at room temperature.
This was followed by four sequential renaturation steps (15 min each)
by discarding half of the volume (50 ml) and replacing it with ice-cold
renaturation buffer (0.05% v/v Tween 20 in buffer A) at 4 °C. After
washing three or four times with 150 ml of renaturation buffer at 4 °C,
the gel was immersed in 25 ml of kinase buffer (20 mM Hepes, pH 7.6,
20 mMMgCl2, 5 mM b-glycerophosphate, 0.1 mM sodium vanadate, 2 mM
dithiothreitol) for 30 min at 4 °C and incubated further in 15 ml of
kinase buffer containing 20 mM ATP and 100 mCi of [g-32P]ATP at 30 °C
for 1–2 h. Finally, the gel was washed four times with 150–200 ml of 5%
v/v trichloroacetic acid and 1% v/v sodium pyrophosphate at room
temperature, dried, and exposed for 1–2 days.
RESULTS
Changes in c-fos and c-jun mRNA Levels in Jurkat Cells
Induced by PDTC—Since different antioxidant agents, includ-
ing PDTC, activate AP-1, we analyzed further the effect of
PDTC on c-fos and c-jun mRNA steady state. Kinetic experi-
ments using total RNA from Jurkat cells treated with PDTC
and from cells treated with the combination of the phorbol ester
PMA and the Ca21 ionophore A23187, either pretreated or not
with PDTC, were carried out (Fig. 1A). Incubation with PMA
plus A23187 resulted in transient induction of both c-fos and
c-jun mRNA levels, having maximal values at 30–60 min,
whereas exposure to PDTC caused a prolonged expression of
c-jun mRNA reaching maximal levels between 1 and 4 h and













expression of c-fos mRNA although displaying kinetics differ-
ent from that exerted by the combination of PMA and iono-
phore. Strikingly, the incubation of Jurkat cells with PDTC
prior to stimulation with PMA plus ionophore led to a pro-
longed induction not only of the c-jun mRNA levels, but also of
the c-fos levels, which were, on the other hand, higher than
those obtained with PDTC and PMA-ionophore separately. As
shown previously for other cell types (23, 24, 32), EMSA using
nuclear extracts from Jurkat T cells and a consensus AP-1
probe confirmed that PDTC (and PMA-ionophore) induced
AP-1 DNA binding activity (Fig. 1B) and TRE-dependent tran-
scriptional activation (Fig. 2). Taken together these data indi-
cated that in Jurkat T cells, PDTC is able, by itself, to induce a
transient expression of c-fos, a strong and prolonged expression
of c-jun, and a durable activation of both c-fos and c-jun trig-
gered by PMA plus ionophore.
Effect of PDTC on the Ras/ERK Pathway—The Ras/ERK
pathway is a common route that serves multiple extracellular
signals that activate the SRE of the c-fos promoter (4, 5). Since
the SRE has been shown to act as a primary antioxidant
responsive element that can be activated by PDTC (23), we
analyzed whether the activation of AP-1 by this antioxidant
was mediated through activation of this pathway in Jurkat T
cells. As shown in Fig. 2A, the activation of an AP-1 reporter
construct (273colLuc) in response to PDTC was not affected by
the expression of a dominant negative ras, c-Ha-ras N17 (Fig.
2A). The efficient expression of the ras construct was confirmed
in parallel cotransfections, where expression of c-Ha-ras N17
caused a severe transcriptional inhibition of both a luciferase
plasmid directed by the human IL-2 promoter (Fig. 2C) and the
AP-1 reporter plasmid in response to PMA plus ionophore (data
not shown). Similar experiments were performed to analyze
whether Raf-1 kinase was required for the activation of AP-1
induced by PDTC. AP-1 trans-activation by the antioxidant
was not significantly affected by the expression of a trans-
dominant negative mutant of Raf-1 kinase (Fig. 2B) which
efficiently inhibited the IL-2Luc trans-activation, as well as the
AP-1Luc trans-activation by PMA plus ionophore (Fig. 2D and
data not shown).
To explore whether the signals elicited by PDTC affected
ERK activity, we performed Western blot analysis using anti-
Erk-1, -2 antibodies to detect any possible decrease in the
electrophoretic mobility of ERKs which would be indicative of
its activation (41). PDTC failed to modify the mobility of
ERK-2, which appears to be the predominant ERK isoform
FIG. 1. Effects of PDTC and PMA plus ionophore on RNA levels
of c-fos and c-jun and on AP-1 binding activity. Panel A, dot-blot
analysis using total RNA from Jurkat T cells treated with 50 mM PDTC,
20 ng/ml PMA plus 1 mM A23187 (Io) or pretreated with 50 mM PDTC for
2 h and then stimulated with 20 ng/ml PMA plus 1 mM A23187 for the
times indicated. RNA was hybridized with probes of c-fos, c-jun, and
b-actin. Panel B, nuclear extracts from Jurkat cells treated with 50 mM
PDTC, 20 ng/ml PMA plus 1 mM A23187 for 4 h, and nuclear extracts
pretreated for 2 h with PDTC and then stimulated with PMA plus
A23187 (at the same doses as those used in separate treatments) for an
additional 4 h were incubated with a probe containing the TRE consen-
sus sequence of the CD11c promoter, and complexes were resolved in an
EMSA.
FIG. 2. Roles of Ras and Raf on the AP-1 trans-activation me-
diated by PDTC. Jurkat T cells were cotransfected by lipofection with
5 mg/ml luciferase-based plasmids directed by the AP-1-responsive
(273/163 base pairs) sequence of the collagenase promoter (273colLuc)
(panels A and B) or by the IL-2 promoter (IL-2Luc) (panels C and D)
together with 10 mg/ml expression vectors of the trans-dominant nega-
tive forms of ras (panels A and C) and raf (panels B and D) or its
parental empty vector, pEFBOS, for 12 h. 36 h post-transfection cells
were treated with 50 mM PDTC or 20 ng/ml PMA plus 1 mM A23187 for
an additional 12 h. The results are expressed as relative light units
(R.L.U) measured for 30 s. Results are representative of three inde-
pendent experiments.
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expressed by Jurkat cells (Fig. 3A). As expected, PMA caused a
very rapid transient shift in the mobility of ERK-2 which was
detected as early as 30 s and declined after 1 h of treatment
(Fig. 3A). Interestingly, when Jurkat cells were pretreated with
PDTC and stimulated further with PMA, ERK-2 persisted in
its activated form after 24 h of treatment (Fig. 3A).
The persistent phosphorylation of ERK-2 observed might be
due to an inhibition of the PAC-1 T cell phosphatase, which has
been shown to dephosphorylate ERK-2 in vivo (34, 42). How-
ever, Northern blot analysis indicated that mRNA steady-state
levels of PAC-1, induced early by PMA, were not significantly
affected by previous treatment with PDTC after 90 and 180
min (Fig. 3B) when a complete activation of ERK-2 was found
in cotreated cells (Fig. 3A). Taken together, our results indi-
cated that the Ras/Raf/ERK pathway did not appear to mediate
the effect of the antioxidant PDTC. In addition, the combined
treatment of PDTC and PMA, which has been shown to syner-
gize on AP-1-dependent trans-activation (23, 24) caused a per-
sistent phosphorylation of ERK-2 by mechanisms different
from the inhibition of the gene expression of PAC-1.
Activation of JNK by Antioxidants—Signals leading to T cell
activation by costimulation with phorbol ester and Ca21 iono-
phore or by agonistic antibodies to the T cell receptor-CD3
complex and to CD28 involve the activation of JNKs (43).
Besides the ability to phosphorylate c-Jun (40), JNKs have
recently been shown to phosphorylate ATF-2 (11, 44, 45) and
TCF-Elk-1 (16–19). Thus, JNKs phosphorylate factors involved
in the activation of AP-1 not only by regulating c-jun but also
by c-fos transcription. Therefore, we decided to determine
whether PDTC affected the activity of JNKs, a mechanism that
could account for the observed c-fos and c-jun activation in the
apparent absence of ERK activation. In-gel kinase assays of
GST-c-Jun1–79 revealed activation of the 46- and 55-kDa forms
of JNK in extracts of Jurkat cells treated with PDTC (Fig. 4A).
Strikingly, whereas the treatment with either PMA plus iono-
phore or anti-CD3 plus anti-CD28 resulted in a transient acti-
vation of JNK (Fig. 4, A and B), PDTC exerted a prolonged
activation of JNK which was maintained for at least 8 h (Fig.
4A). To determine whether the activation by PDTC was due to
its antioxidant effect, we then analyzed the effects on JNK
activity of two structurally unrelated antioxidants, N-acetyl-
cysteine and BHA, which have been shown to increase AP-1
activity (23, 24). Exposure of Jurkat cells to BHA resulted in a
weak although sustained activation of JNK which persisted for
more than 4 h (Fig. 4D). Treatment with N-acetylcysteine led,
on the other hand, to a transient activation of JNK, although in
this case it was even stronger than that mediated by PMA plus
ionophore (Fig. 4C). Thus, signals triggered by different anti-
oxidant agents that increase or activate AP-1 involve the acti-
vation of JNK.
Inhibitors of T Cell Activation Discriminate the Signaling
Pathways of PDTC versus PMA plus Ionophore—To search for
mechanisms involved in the activation of JNK by antioxidant
agents, a panel of inhibitors that interfere with upstream sig-
nals involved in T cell activation was used. Thus, inhibition of
protein tyrosine kinases with herbimycin A resulted in signif-
icant inhibition of the JNK activation mediated by PMA plus
ionophore (Fig. 5A) and by anti-CD3 plus anti-CD28 antibodies
(data not shown), but it did not interfere with that mediated by
PDTC. In addition, blockade of the Ca21/calcineurin signaling
pathway with cyclosporin A, which has been shown to attenu-
ate JNK activation in response to either PMA plus ionophore or
anti-CD3 plus anti-CD28 (43), had no effect on PDTC-mediated
JNK activation at the doses analyzed (Fig. 5, A and B, and data
not shown). Moreover, inhibition of PKC with bisindolylmale-
imide (46), which completely abrogated the activation of JNK
induced by PMA plus ionophore (Fig. 5A), had the opposite
effect on the PDTC-mediated activation, resulting in increased
JNK activity when bisindolylmaleimide was added (Fig. 5B).
This effect, which was not observed either with extracts from
cells treated with PMA plus ionophore, with anti-CD3 plus
anti-CD28 cells, or with control cells pretreated with the PKC
inhibitor (Fig. 5A and data not shown), requires further study.
Nevertheless, the effect of bisindolylmaleimide clearly discrim-
inates the signaling pathways induced by PDTC versus PMA
plus ionophore. Thus, the signals that converge in JNK activa-
tion mediated by PDTC appear to be distinct from those elicited
FIG. 3. Effects of PDTC and PMA on ERK activity and PAC-1
gene expression. Panel A, Western blot analysis of total lysates from
Jurkat cells (106) incubated with 50 mM PDTC, 20 ng/ml PMA, or
preincubated with 50 mM PDTC for 2 h and then treated with 20 ng/ml
PMA for the times indicated. A monoclonal antibody against ERK-1 and
ERK-2 was used. The electrophoretic mobility of the upper and lower
bands corresponded to the phosphorylated and unphosphorylated
bands of ERK-2, respectively. Panel B, total cytoplasmic RNAs (10 mg)
from Jurkat cells treated as described in panel A were prepared at
different times of treatment and subjected to Northern blot analysis
using a probe specific for PAC-1.
FIG. 4. Activation of JNK by antioxidants and T cell stimuli.
In-gel kinase assay performed with whole-cell extracts from Jurkat
cells (106) treated with 20 ng/ml PMA plus 1 mM A23187 (P1Io), or 100
mM PDTC (panel A), 10 mg/ml anti-CD3 plus 2 mg/ml anti-CD28 (panel
B), 50 mM N-acetylcysteine (NAC, panel C), and 50 mM BHA (panel D)
for the times indicated. Controls from untreated and PMA plus iono-
phore-treated cells are included in each experiment to compare the
relative induction obtained with the different antioxidants. Whole-cell
extracts were separated by SDS-polyacrylamide gel electrophoresis on a
gel polymerized in the presence of GST-c-Jun1–79. After a denaturation-
renaturation process, the gel was incubated with [g-32]ATP, washed
extensively, and exposed. The bands corresponding to the 46- and













through stimulation of T cells with PMA plus ionophore or
anti-CD3 plus CD28.
DISCUSSION
The physiological and pharmacological modifications of the
cellular redox state provoke drastic changes in the activities of
the transcription factors AP-1 and NFkB which play a central
role in the regulation of the immune response. NFkB and AP-1
are affected differentially by signals generated by prooxidant
and antioxidant agents (20); whereas NFkB is induced by a
large number of T cell stimuli that cause reactive oxygen in-
termediate generation (20, 47), its activation is inhibited by
different antioxidant agents with radical scavenger properties.
However, AP-1 is not only induced by a wide array of stimuli
that generate oxidative stress (23, 28–31), but also by a num-
ber of antioxidant agents (23–25, 32). In this study, we com-
pared the signaling pathways through which antioxidants and
T cell stimuli lead to the activation of AP-1 and identify JNK as
a target activated by different antioxidant agents.
Although treatment of Jurkat T cells with either PMA plus
ionophore or anti TCR/CD3 plus CD28 on one hand and with
antioxidants on the other increases the activity of JNK, our
data clearly indicate that the signal transduction mechanisms
involved in both activations are different. (i) JNK activation by
PDTC was refractory to inhibitors of protein tyrosine kinases,
protein kinase C, or Ca21 signaling, whereas the JNK activa-
tion mediated by either T cell receptor-CD3/CD28 antibodies or
PMA plus ionophore was inhibited to a variable extent by such
inhibitors. (ii) TRE and IL-2 promoter-mediated trans-activa-
tion by PMA and ionophore was sensitive to the expression of
trans-dominant negative versions of ras and raf which failed to
inhibit the AP-1 trans-activation induced by PDTC. (iii) Tran-
sient phosphorylation of ERK-2, detected at early times of
activation with PMA, was not observed after treatment with
PDTC.
Although the expression of c-Ha-ras N17 dominant negative
did not affect the trans-activation of AP-1 by PDTC (Fig. 2A),
this was augmented by the expression of a constitutively active
v-Ha-ras (data not shown). Since activated Ha-ras has been
shown to partially activate JNK (10), it is likely that the addi-
tional effect displayed by activated ras on the activation of AP-1
by PDTC is mediated through JNK. Hence, the Ras/Raf/ERK
pathway can modulate the PDTC-induced signaling to AP-1,
although it did not appear to mediate the effect of the
antioxidant.
An interesting feature of ERK regulation arising during the
analysis of its phosphorylation in extracts of Jurkat cells co-
treated with PMA and PDTC was the persistent activated state
of ERK-2. Whether this prolonged activation is related to the
synergism observed on the activation of AP-1 by both agents
(23, 24) remains to be investigated further. Since PAC-1 is a
phosphatase rapidly expressed after T cell activation which has
been shown to inhibit ERK-2 phosphorylation and activation
(34, 42), we have analyzed its involvement in the activation
induced by PMA plus PDTC. However, our studies on PAC-1
gene expression indicated that PAC-1 mRNA levels induced by
PMA were not significantly affected by PDTC (Fig. 3B). Other
explanations that could account for the constitutive activation
of ERK include the possibility that PAC-1 phosphatase activity
was post-transcriptionally inhibited by PDTC, or more likely,
that other phosphatases could be inhibited by the antioxidant.
In this regard, the expression of mitogen-activated protein
kinase phosphatase-1 in T lymphocytes has recently been
shown to block PMA-induced ERK activity and to inhibit IL-2
promoter-dependent transcription in response to PMA plus
ionophore (48). Since mitogen-activated protein kinase phos-
phatase-1 has also been shown to dephosphorylate JNK (49), it
will be of interest to study the activity and expression of this
phosphatase in response to antioxidants.
In HeLa cells PDTC has been shown to induce c-fos and c-jun
transcription (23). Although we have found induction of both
c-fos and c-jun by PDTC in Jurkat cells, important kinetic
differences are observed when both cell types are compared.
Thus, in HeLa cells PDTC triggers c-fos gene expression faster
than c-jun, with a transient induction in both cases (23). How-
ever, in Jurkat cells PDTC-mediated c-jun expression was pro-
longed and preceded that of c-fos. Therefore, PDTC can operate
by different mechanisms depending on the cell type analyzed.
The SRE within the c-fos promoter has been shown to act as
a primary antioxidant element that can be activated by PDTC
in HeLa cells (23). However, as discussed above, the mecha-
nisms by which the antioxidant acted in Jurkat cells does not
appear to be mediated by the Ras/Raf/ERK pathway. Hence,
PDTC seems to be one of the stimuli that can induce c-fos in the
absence of ERK activation. Since JNK has been shown to
phosphorylate TCF/Elk-1, the major transcription factor in-
volved in SRE activation, it is possible that PDTC can activate
c-fos transcription through the phosphorylation of TCF by
JNK. Additional experiments, including in-gel kinase analysis
of GST-Elk-1 in extracts of cells treated with antioxidants, will
be required to elucidate this issue.
We have found that structurally unrelated antioxidant
agents activate JNK in Jurkat T cells. However, the kinetics
and strength of this activation as well as the abilities to stim-
ulate AP-1 displayed by the different antioxidants are differ-
ent. Thus, PDTC per se exerts a potent and prolonged JNK
activation and activates both AP-1 DNA binding activity and
the TRE-dependent trans-activation. BHA displays a weak but
sustained activation of JNK; and N-acetylcysteine, which has
been shown to induce AP-1 binding but not significant TRE
trans-activation (23), exerts a transient activation of JNK.
Moreover,N-acetylcysteine was the strongest antioxidant stim-
ulating JNK. Therefore, sustained activation of JNK appears to
be a mechanism through which some antioxidants can operate,
but it is not a general mechanism that mediates the signaling
of all of the antioxidants. Likewise, these results suggest that
additional signaling, different from JNK activation, must be
FIG. 5. Effects of T cell activation inhibitors on the JNK activ-
ity induced by PDTC and T cell stimuli. In-gel kinase assays were
performed with whole-cell extracts from Jurkat cells preincubated or
not with 10 mM bisindolylmaleimide (BSM), 100 ng/ml cyclosporin A
(CsA), or 800 nM herbimycin A (Herb) for 4, 1, and 12 h, respectively.
After preincubation, cells were treated with 20 ng/ml PMA plus 1 mM
A23187 (P1Io) for 15 min (panel A) or with 20 and 100 mM PDTC for 2 h
(panel B). Whole-cell extracts were then obtained, and an in-gel kinase
assay of GST-c-Jun1–79 was performed. The bands corresponding to the
55- and 46-kDa forms of JNK are indicated by arrowheads.
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required to activate TRE-dependent transcription, since N-
acetylcysteine, which is not able to activate it per se (23, and
data not shown), activates JNK in a fashion similar to that of
PMA plus ionophore.
It is important to note that both prooxidant and antioxidant
conditions lead to the activation of AP-1. JNK appears to be
tuned differentially under both conditions. Thus, it would be
possible that those antioxidants that trigger sustained activa-
tion of JNK might elicit specific antioxidative responses
through AP-1-regulated genes, subtly regulated by the dura-
tion and the strength of JNK stimulation. In this regard, in
PC12 cells the cellular responses elicited by growth factors
which lead cells to proliferate or to differentiate seem to be
determined by the transient or sustained activation of ERK,
respectively (5). On the other hand, we have shown recently
that several dithiocarbamates, including PDTC, trigger mye-
loid differentiation involving the activation of AP-1 (32). Hence,
it will be of the utmost interest to determine whether the
duration of JNK activation is involved in selectively triggering
these cellular responses.
Future experiments will be designed to identify the mecha-
nisms by which antioxidants target JNK activity including
their effects on the upstream signaling pathway components
that activate JNK/SAPKs and on the phosphatases that regu-
late its phosphorylation. These studies, which could also con-
tribute to trace the signal transduction mechanisms involved in
T lymphocyte activation, are currently in progress.
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